SosipatrosBoikosMD
Oncology • Washington, DCCancer Genetics/Cancer Risk Assessment, Endocrine Cancer, Sarcoma
Medical Oncologist, Co-Leader, Sarcoma Working Group, Washington Hospital Center, Georgetown University Hospital, Georgetown Lombardi Comprehensive Sarcoma Group
Dr. Boikos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
110 Irving St NW
Washington, DC 20010Phone+1 240-418-8300
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2011 - 2014
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2008 - 2011
University of Crete School of Health SciencesClass of 2002
Certifications & Licensure
VA State Medical License 2014 - 2026
DC State Medical License 2021 - 2024
MD State Medical License 2011 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Venetoclax and Irinotecan in Relapsed/Refractory SCLC Start of enrollment: 2021 Jun 30
Publications & Presentations
PubMed
- 145 citationsRecurrent epimutation of SDHC in gastrointestinal stromal tumors.J. Keith Killian, Markku Miettinen, Robert L. Walker, Yonghong Wang, Yuelin Jack Zhu
Science Translational Medicine. 2014-12-24 - Thyroid hormone inactivation in gastrointestinal stromal tumorsSosipatros A. Boikos, Lee J. Helman, Constantine A. Stratakis
The New England Journal of Medicine. 2014-07-03 - 25 citationsSystemic Therapy, Clinical Outcomes, and Overall Survival in Locally Advanced or Metastatic Pulmonary Carcinoid: A Brief ReportPatrick M. Forde, Craig M. Hooker, Sosipatros A. Boikos, Iacope Petrini, Giuseppe Giaccone
Journal of Thoracic Oncology. 2014-03-01
Journal Articles
- The Ewing Family of Tumors Rely on BCL-2 and BCL-XL to Escape PARP Inhibitor ToxicitySteven C Smith, Sosipatros A Boikos, Anthony C Faber, Clinical Cancer Research
- Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug TargetAaron N Hata, Sosipatros A Boikos, Anthony C Faber, Clinical Cancer Research
Press Mentions
What Is a Sarcoma? Tips for Navigating This Rare Type of CancerFebruary 24th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
